现在的位置: 首页时讯速递, 进展交流>正文
[Chest发表论文]:成年脓毒症患者的小或大容量液体复苏
2023年11月13日 时讯速递, 进展交流 [Chest发表论文]:成年脓毒症患者的小或大容量液体复苏已关闭评论

CRITICAL CARE: ORIGINAL RESEARCH| VOLUME 164, ISSUE 4, P892-912, OCTOBER 2023

Lower vs Higher Fluid Volumes in Adult Patients With Sepsis: An Updated Systematic Review With Meta-Analysis and Trial Sequential Analysis

Praleene Sivapalan, Karen L. Ellekjaer, Marie K. Jessen, et al

Chest 2023; 164: 892-912 Open Access Published:May 02, 2023

DOI:https://doi.org/10.1016/j.chest.2023.04.036

Background

IV fluids are recommended for adults with sepsis. However, the optimal strategy for IV fluid management in sepsis is unknown, and clinical equipoise exists.

Research Question

Do lower vs higher fluid volumes improve patient-important outcomes in adult patients with sepsis?

Study Design and Methods

We updated a systematic review with meta-analysis and trial sequential analysis of randomized clinical trials assessing lower vs higher IV fluid volumes in adult patients with sepsis. The coprimary outcomes were all-cause mortality, serious adverse events, and health-related quality of life. We followed the recommendations from the Cochrane Handbook and used the Grading of Recommendations Assessment, Development and Evaluation approach. Primary conclusions were based on trials with low risk of bias if available.

Results

We included 13 trials (N = 4,006) with four trials (n = 3,385) added to this update. The meta-analysis of all-cause mortality in eight trials with low risk of bias showed a relative risk of 0.99 (97% CI, 0.89-1.10; moderate certainty evidence). Six trials with predefined definitions of serious adverse events showed a relative risk of 0.95 (97% CI, 0.83-1.07; low certainty evidence). Health-related quality of life was not reported.

Interpretation

Among adult patients with sepsis, lower IV fluid volumes probably result in little to no difference in all-cause mortality compared with higher IV fluid volumes, but the interpretation is limited by imprecision in the estimate, which does not exclude potential benefit or harm. Similarly, the evidence suggests lower IV fluid volumes result in little to no difference in serious adverse events. No trials reported on health-related quality of life.

Trial Registration

PROSPERO; No.: CRD42022312572; URL: https://www.crd.york.ac.uk/prospero/

抱歉!评论已关闭.

×
腾讯微博